EVO ICL is FDA-approved for patients ages 21 to 60 — a range that was recently expanded from the previous upper limit of 45, making this procedure available to a significantly broader group of patients. Ideal candidates are nearsighted, with prescriptions typically ranging from -3.00 to -20.00 diopters, with or without astigmatism. Good candidates also have stable vision for at least one year and no history of certain eye conditions such as glaucoma or cataracts. EVO ICL does not correct farsightedness. At Florida Eye Custom Vision, Drs. Chokshi and Hasan perform a comprehensive pre-operative evaluation — including Pentacam and Sightmap imaging — to confirm candidacy before any recommendation is made.
— Dr. Amit Chokshi, MD & Dr. S. Akbar Hasan, MD, Florida Eye Custom Vision